+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Diagnostic Imaging Partnering Terms and Agreements 2015 to 2022

  • PDF Icon

    Report

  • 500 Pages
  • June 2022
  • Region: Global
  • CurrentPartnering
  • ID: 2907759
The Global Diagnostic Imaging Partnering Terms and Agreements 2015 to 2022 report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter diagnostic imaging partnering deals. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:

  • Imaging
  • CT
  • Endoscope
  • Molecular and nuclear
  • PET
  • SPECT
  • MRI
  • Ultrasound
  • X ray
  • Angiography
  • Fluoroscopy
  • Mammography

This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review of deals signed in since 2015.

This report provides a comprehensive and detailed review of all diagnostic imaging deals announced since 2015. The comprehensive agreements chapter is organized by company A-Z, stage of development at signing, deal type, and therapy focus. Each deal title links via Weblink to an online version of the actual deal at Current Agreements deals and alliances database, providing easy access to each deal on demand. Where available, the full deal contract document is also provided and indicated by a document symbol.

Contract documents provide unsurpassed access to the detail of a deal normally announced in brief summary through a press release. Detailed analysis of a contract allow better understanding of the terms agreed between the parties, and importantly the basis under which monies and licensing rights are exchanged.

The initial chapters of this report provide an orientation of Diagnostic Imaging dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Diagnostic Imaging dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Diagnostic Imaging deals since 2015. Deals are listed by headline value, signed by big pharma, most active Diagnostic Imaging dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Diagnostic Imaging dealmaking with a brief summary followed by a comprehensive listing of Diagnostic Imaging deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Diagnostic Imaging partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Diagnostic Imaging partnering deals signed and announced since Jan 2015. The chapter is organized by specific Diagnostic Imaging technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Diagnostic Imaging partnering company A-Z, deal type definitions and Diagnostic Imaging partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostic Imaging partnering and dealmaking since 2015.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Diagnostic Imaging technologies and products.

Key benefits


Global Diagnostic Imaging Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of diagnostic deal trends since 2015
  • Comprehensive access to over 900 actual diagnostic imaging deals entered into by the world’s biopharma companies
  • Detailed access to actual diagnostic contracts enter into by the leading biopharma companies
  • Insight into the terms included in a diagnostic agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope


Global Diagnostic Imaging Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the diagnostic imaging trends and structure of deals entered into by leading companies worldwide.

Global Diagnostic Imaging Partnering Terms and Agreements includes:

  • Trends in diagnostic imaging dealmaking in the biopharma industry since 2015
  • Access to over 900 diagnostic imaging contract documents
  • The leading diagnostic imaging deals by value since 2015
  • Most active diagnostic imaging dealmakers since 2015
  • The leading diagnostic imaging partnering resources

In Global Diagnostic Imaging Partnering Terms and Agreements, the available contracts are listed by:

  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Specific technology target

Each deal title links to online deal records of actual diagnostic imaging partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The Global Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive access to available contract documents for over 900 diagnostic imaging deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise diagnostic rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in Diagnostic Imaging dealmaking
2.1. Introduction
2.2. Diagnostic Imaging partnering over the years
2.3. Most active Diagnostic Imaging dealmakers
2.4. Diagnostic Imaging partnering by deal type
2.5. Diagnostic Imaging partnering by therapy area
2.6. Deal terms for Diagnostic Imaging partnering
2.6.1 Diagnostic Imaging partnering headline values
2.6.2 Diagnostic Imaging deal upfront payments
2.6.3 Diagnostic Imaging deal milestone payments
2.6.4 Diagnostic Imaging royalty rates
Chapter 3 - Leading Diagnostic Imaging deals
3.1. Introduction
3.2. Top Diagnostic Imaging deals by value
Chapter 4 - Most active Diagnostic Imaging dealmakers
4.1. Introduction
4.2. Most active Diagnostic Imaging dealmakers
4.3. Most active Diagnostic Imaging partnering company profiles
Chapter 5 - Diagnostic Imaging contracts dealmaking directory
5.1. Introduction
5.2. Diagnostic Imaging contracts dealmaking directory
Chapter 6 - Diagnostic Imaging dealmaking by technology type
Appendices
Appendix 1 - Diagnostic Imaging deals by company A-Z
Appendix 2 - Diagnostic Imaging deals by stage of development
Appendix 3 - Diagnostic Imaging deals by deal type
Appendix 4 - Diagnostic Imaging deals by therapy area
Appendix 5 - Deal type definitions
Appendix 6 - Further Reading
Table of figures
Figure 1: Diagnostic Imaging partnering since 2015
Figure 2: Active Diagnostic Imaging dealmaking activity- 2015 to 2022
Figure 3: Diagnostic Imaging partnering by deal type since 2015
Figure 4: Diagnostic Imaging partnering by disease type since 2015
Figure 5: Diagnostic Imaging deals with a headline value
Figure 6: Diagnostic Imaging deals with an upfront value
Figure 7: Diagnostic Imaging deals with a milestone value
Figure 8: Diagnostic Imaging deals with a royalty rate value
Figure 9: Top Diagnostic Imaging deals by value since 2015
Figure 10: Most active Diagnostic Imaging dealmakers 2015 to 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 3B Pharmaceuticals
  • 3Derm Systems
  • 3DR Labs
  • 3M
  • 7D Surgical
  • 22nd Century
  • AAM Healthcare
  • Abbott Laboratories
  • Abbvie
  • Abcam
  • Abramson Cancer Center
  • Acacia Research
  • Accudata Systems
  • Accuray
  • Acibadem University
  • AC Immune
  • ACIST Medical Systems
  • Acoustic MedSystems
  • Actelion
  • Acutus Medical
  • AdAlta
  • Adaptiiv
  • Advanced Accelerator Applications
  • Advanced Animal Diagnostics
  • Advanced Cell Diagnostics
  • Advanced Chemistry Development
  • Advanced Guidance Technologies
  • Advanced Human Imaging
  • Advanced Nuclear Medicine Ingredients
  • Advanced Ultrasound Systems
  • Agfa HealthCare
  • Agilent Technologies
  • AG Mednet
  • Aidoc
  • Aiforia Technologies
  • AIG Hospitals
  • AI Metrics
  • AIM Specialty Health
  • Aircraft Medical
  • Akoya Biosciences
  • Akumin
  • Albany Molecular Research
  • Albert Einstein College of Medicine
  • Albert Einstein Healthcare Network
  • Alector
  • Alfasigma
  • Alibaba Health
  • Align Technology
  • AliHealth
  • Allegheny Technologies
  • Allergan
  • Alphaeon
  • Alpha Imaging
  • Alpinion Medical Systems
  • Altris
  • Alume Biosciences
  • Alzeca Biosciences
  • Alzheimer's Association
  • Alzheimer's Drug Discovery Foundation
  • Alzheimers Research UK
  • Amag Pharmaceuticals
  • Ambergen
  • Ambra Health
  • Ambry Genetics
  • Ambu
  • AmCad BioMed
  • A Menarini Diagnostics
  • American Brain Tumor Association
  • American College of Cardiology
  • American College of Chest Physicians
  • American Health Imaging
  • American Migraine Foundation
  • Amerinet
  • AMRA
  • AMRA Medical
  • Amydis
  • Analytics 4 Life
  • AnchorDx
  • Andor Technology
  • Antaros Medical
  • Applied Spectral Imaging
  • APRINOIA Therapeutics
  • Arc Medical Design
  • Aridea Solutions
  • Arivis
  • Arterys
  • Artialis
  • ARTMS Product
  • ARUP Laboratories
  • Ashvattha Therapeutics
  • Aspect Imaging
  • Aspen Imaging Healthcare
  • AstraZeneca
  • Athinoula A Martinos Center for Biomedical Imaging
  • Austin Health
  • Avantis Medical Systems
  • Avicenna Technology
  • AVRA Surgical
  • Aytu BioPharma
  • AZ Sint Lucas Hospital
  • BAMF Health
  • Banner Health
  • Baptist Health Care
  • Baxter International
  • Bayer
  • Bay Labs
  • Baylor College
  • Baylor College of Medicine
  • BayPAT
  • BC Technical
  • Beijing Podconley Pharmaceutical Technology and Development
  • BeMotion
  • Bethyl Laboratories
  • Biim Ultrasound
  • Bill and Melinda Gates Foundation
  • BioArctic Neuroscience
  • BioClinica
  • Biogen
  • Biokosmos
  • BIOLIFE4D
  • Biolife Science
  • BioMark Diagnostics
  • BiopharmX
  • Bioscience Pharma Partners
  • Biotechnology Innovation Organization
  • BioTek Instruments
  • BioTelemetry
  • Bioverativ
  • BJC HealthCare
  • Blackford
  • Blackfynn
  • BlackThorn Therapeutics
  • Blue Earth Diagnostics
  • Boehringer Ingelheim
  • BostonGene
  • Boston Medical Center
  • Boston Scientific
  • Bpifrance
  • Bracco Diagnostics
  • Bracco Imaging
  • Brain & Behavior Research Foundation
  • BRAIN Initiative
  • BrainLAB
  • Brainomix
  • Brain Scientific
  • BriaCell Therapeutics
  • Brigham and Women's Hospital
  • Broad Institute
  • Bruker
  • Bruker AXS
  • Bruker Energy & Supercon Technologies (BEST)
  • Butantan Institute
  • Butterfly Network

Methodology

  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

 

 

Loading
LOADING...